

Truxima approved as first biosimilar to non-Hodgkin's lymphoma drug

November 29 2018

(HealthDay)—Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday.

A biosimilar is a biological product that is approved based on data showing it is "highly similar" to a drug already approved by the FDA, with no "clinically meaningful differences in terms of safety, purity and potency," the agency said in a news release.

Truxima, as with Rituxan, is approved to treat adults with CD20-positive, B-cell non-Hodgkin's lymphoma. The most common side effects of Truxima are infusion reactions, fever, low blood lymphocytes, chills, infection and weakness.

The drug's label includes a boxed warning that [users](#) also may be at increased risk of fatal infusion reactions, severe skin and mouth reactions, reactivation of hepatitis B, and a rare deadly brain infection known as PML.

Users should not receive [vaccinations](#) while in treatment with Truxima, the agency warned, adding that women who are pregnant or breastfeeding shouldn't take the [drug](#).

Truxima is produced by the South Korean drugmaker Celltrion. Rituxan, produced by the San Francisco firm Genentech, was approved in 1997.

More information: Visit the [FDA](#) to learn more.

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Truxima approved as first biosimilar to non-Hodgkin's lymphoma drug (2018, November 29) retrieved 26 April 2024 from <https://medicalxpress.com/news/2018-11-truxima-biosimilar-non-hodgkin-lymphoma-drug.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.